Table 1.

Influential clinical trials and studies in CAR-T therapy

NO	Institution	NCT	Author	Year	Journal	No.pts	Condition	Target	CD*	Dose	LD*
13	Upeen & CHOP	NCT01626495	Grupp	2013	N Engl J Med	2	B-ALL	CD19	4-1BB	1.4 × 106 - 1.2 × 107/Kg	N/A
			Fitzgerald	2016	Crit Care Med	39	B-ALL
			Gofshteyn	2018	Ann Neurol	51	ALL
		NCT02435849 (ELIANA)	Maude	2018	N Engl J Med	75	B-ALL	CD19	4-1BB	0.2 × 106 - 5.4 × 106/Kg	FC*
			Laetsch	2019	Lancet Oncol	58
		NCT02445248 (JULIET)	Schuster	2019	N Engl J Med	93	DLBCL	CD19	4-1BB	N/A	N/A
			Bishop	2019	Blood Adv	7
		NCT01029366	Porter	2015	Sci Transl Med	14	CLL	CD19	4-1BB	0.142 × 108–11.3 × 108	Flu*/Cy*/Bendamustine/Pentostatin
		NCT02030834	Schuster	2017	N Engl J Med	28	DLBCL	CD19	4-1BB	1–5 × 108	N/A
		NCT01626495 NCT01029366	Maude	2014	N Engl J Med	51	see in NCT01626495 & NCT01029366
		NCT02030847** NCT01626495 NCT01029366	Teachey	2016	Cancer Discov	51	ALL	CD19	4-1BB	1.0 × 107 - 5.0 × 108	N/A
		NCT01747486** NCT01029366	van Bruggen	2019	Blood	27	CLL	CD19	4-1BB	1.0 × 107 - 5.0 × 108	N/A
		NCT02640209** NCT01747486 NCT01029366	Fraietta	2018	Nat Med	41	CLL	CD19	4-1BB	1.0 × 108 - 5.0 × 108	N/A
8	FHCRC	NCT01865617	Turtle	2016	J Clin Invest	30	B-ALL	CD19	4-1BB	2 × 106/Kg	FC
				2016	Sci Transl Med	32	NHL
				2017	J Clin Oncol	24	CLL
			Gust	2017	Cancer Discov	133	B-ALL & NHL & CLL
			Hay	2017	Blood	133	B-ALL & NHL & CLL
				2019	Blood	53	B-ALL
			Hirayama	2019	Blood	21	NHL
				2019	Blood	65	NHL
7	NCI	NCT00924326	Kochenderfer	2017	J Clin Oncol	22	NHL&CLL	CD19	CD28	1.0 × 106–6.0 × 106/kg	FC
				2015	J Clin Oncol	15	NHL&CLL
			Rossi	2018	Blood	22	NHL
		NCT01593696	Lee	2015	Lancet	21	ALL&NHL	CD19	CD28	1.0 × 106 or 3.0 × 106/kg	FC
		NCT02215967	Ali	2016	Blood	12	MM	BCMA	CD28	9.0 × 106/kg	FC
			Brudno	2018	J Clin Oncol	16
		NCT02315612	Fry	2018	Nat Med	15	B-ALL	CD19 & CD22	4-1BB	≥1 × 106/Kg	FC
5	MSKCC	NCT01044069	Brentjens	2013	Sci Transl Med	5	B-ALL	CD19	CD28	1.0 × 106–3.0 × 106/kg	FC/Cy/ Cy + clofarabine
			Davila	2014	Sci Transl Med	16
			Park	2018	N Engl J Med	53
				2018	Clin Infect Dis	53
			Santomasso	2018	Cancer Discov	53
3	SCRI	NCT02028455	Gardner	2017	Blood	45	B-ALL	CD19	CD28	0.5 × 106–10.0 × 106/kg	Flu/Cy
				2016	Blood	7
			Finney	2019	J Clin Invest	43
3	Moffitt Cancer Center	NCT02348216 (ZUMA-1)	Locke	2017	Mol Ther	7	NHL	CD19	CD28	2 × 106/Kg	FC
				2019	Lancet Oncol	108
	M.D.Anderson Cancer Center		Neelapu	2017	N Engl J Med	101

*: CD: costimulatory domain; LD: lymphodepletion; Cy: cyclophosphamide; Flu: fludarabine; FC: fludarabine+ cyclophosphamide

**: the NCT trial of CAR-T therapy described in this row